Full side-by-side comparison — 2026
Data as of Jul 24, 2026 · Updated automatically
| Metric | ABBV | PEP |
|---|---|---|
| Current Price | 261.14 | 138.14 |
| Previous Close | 259.29 | 136.64 |
| Metric | ABBV | PEP |
|---|---|---|
| Trailing P/E | 126.52 | 17.76 |
| Forward P/E | 15.93 | 15.02 |
| Price / Book | -68.85 | 8.64 |
| Price / Sales | 7.29 | 1.90 |
| EV / EBITDA | 17.44 | 12.02 |
| Metric | ABBV | PEP |
|---|---|---|
| Dividend Yield | 0.0272% | 0.0420% |
| Dividend Rate (Annual) | 6.83 | 5.75 |
| 5-Year Avg Yield | 3.96% | 2.85% |
| Payout Ratio | 3.2476% | 0.7448% |
| Metric | ABBV | PEP |
|---|---|---|
| Beta (Volatility) | 0.28 | 0.37 |
| Debt / Equity | 4789.60 | 238.95 |
| Quick Ratio | 0.52 | 0.69 |
| Current Ratio | 0.80 | 0.93 |
| Metric | ABBV | PEP |
|---|---|---|
| Revenue Growth | 0.1240% | 0.0640% |
| Earnings Growth | -0.4620% | 1.3700% |
| Return on Equity | 62.2500% | 0.5151% |
| Revenue / Share | 35.50 | 70.89 |
| Trailing EPS | 2.05 | 7.60 |
| Forward EPS | 16.28 | 8.99 |
| Metric | ABBV | PEP |
|---|---|---|
| Analyst Mean Target | 267.79 | 155.73 |
| Analyst High Target | 328.00 | 183.00 |
| Analyst Low Target | 200.00 | 124.00 |
PepsiCo, Inc. (PEP) leads on 12 of 19 comparable metrics.
PepsiCo, Inc. is the stronger pick for value investors, while AbbVie Inc. may appeal to growth investors.
This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.
ABBV trades at 126.5x earnings vs PEP at 17.8x — a gap this large often reflects different growth expectations, not simple mispricing.
ABBV carries 4790x debt-to-equity — significantly higher than PEP's 239x. High leverage amplifies both gains and losses.
ABBV's earnings declined 46% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.
Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare …
View ABBV details →PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of various beverages and convenient foods worldwide. The company operates through six segments: PepsiCo Foods North America; PepsiCo Beverages North America; International Beverages Franchise; Europe, Middle East and Africa; Latin America Foods; and Asia Pacific Foods. It offers cereals, chips, dips, granola bars, oatmeal, pasta, rice, and syrups and mixes; refrigerated dips and spreads; beverage concentrates, fountain syrups, and finished goods; and ready-to-drink tea and coffee products. The company also …
View PEP details →Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.
Start Free Portfolio